ZyVersa Therapeutics

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Weston, Florida. The company focuses on the development of therapies for inflammatory and renal diseases. ZyVersa was founded in 2014. It became a publicly traded entity on the Nasdaq stock exchange under the ticker symbol ZVSA in December 2022, following a business combination with Larkspur Health Acquisition Corp. The company's leadership includes Stephen C. Glover, who serves as Chairman and Chief Executive Officer. His extensive background in the biopharmaceutical sector, which includes roles at companies like Gencia and Insmed, provides ZyVersa with experienced direction. The scientific foundation of the company is significantly shaped by the work of its Chief Scientific Officer, Dr. Floyd R. Sallee, and Dr. Nicholas J. T. Tsinoremas, who is a co-inventor of the Cholesterol Efflux Mediator™ VAR 200. ZyVersa's therapeutic pipeline is built around two primary platforms. The first is the Inflammasome ASC Inhibitor IC 100, a monoclonal antibody designed to inhibit the ASC component of inflammasomes. By targeting the inflammasome, which is implicated in initiating and perpetuating inflammation, IC 100 has potential applications in a wide range of inflammatory conditions, including neurological and respiratory diseases. The second platform is the Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin), which is being developed to treat renal conditions, most notably Focal Segmental Glomerulosclerosis (FSGS). VAR 200 aims to ameliorate kidney damage by removing excess lipids, thereby protecting the podocytes, which are crucial for kidney filtration. The business model is typical of a clinical-stage biopharmaceutical firm, where value is created by advancing drug candidates through the rigorous phases of clinical trials, with the ultimate goal of obtaining regulatory approval and commercializing these therapies. Revenue generation is contingent upon achieving these milestones, potentially through partnerships, licensing agreements, or direct sales following market approval. Keywords: biopharmaceutical, inflammasome inhibitor, renal disease, clinical-stage, ASC inhibitor, Cholesterol Efflux Mediator, FSGS, monoclonal antibody, drug development, inflammatory disease